23andMe Holding Co. announced the appointment of Reza Afkhami as its Chief Corporate Development Officer overseeing corporate development efforts across its therapeutics, research services and consumer groups. Afkhami will be responsible for spearheading and driving a wide range of industry collaborations for the Company.

Before joining 23andMe, Afkhami was Senior Vice President of Corporate Development and Strategy at Global Blood Therapeutics Afkhami brings over 20 years of corporate strategy and business development experience across the therapeutics industry. Prior to Global Blood Therapeutics, Afkhami served as Vice President of Corporate Development and Strategy at Surrozen. He has held numerous positions overseeing global commercial strategy and planning, led teams handling business development and market intelligence, and managed and supported partnerships to help to grow a company from early-stage drug discovery to a fully integrated biopharmaceutical company.

Afkhami holds a Bachelor of Science (BS) degree from Georgetown University, and a Master of Business Administration (MBA) degree from the University of California, Berkeley.